Eli Lilly reported results that beat street forecasts, driven by blockbuster performance of its GLP‑1 portfolio. Combined 2025 sales of Lilly’s obesity medicines—Zepbound and Mounjaro—surpassed $36 billion, and management issued 2026 guidance that outpaced consensus, reflecting continued market momentum and pricing resilience. The strength of Lilly’s obesity franchise pushed its stock higher and set a high bar for rivals, intensifying the commercial race across GLP‑1 and next‑generation metabolic programs. Investors and competitors are recalibrating expectations for market share, pricing negotiations and the cadence of new launches across the obesity category.